General information
Age, yrs 64.7 ± 12.3
Females, n (%) 289 (85%)
BMI, kg/m2 22.4 ± 3.8
Hypertension, n (%) 126 (37.1%)
Diabetes mellitus, n (%) 32 (9.4%)
Dyslipidemia, n (%) 133 (39.1%)
Smoking, n (%) 116 (34.1%)
Inflammatory markers
ESR, mm/h 20.6 ± 17.2
CRP, mg/dL 0.44 ± 1.06
RA characteristics
Duration of RA, days 3,563 [1,733–7,547]
RF-positive, n (%) 255 (75.0%)
ACPA-positive, n (%) 265 (77.9%)
Patient VAS 24.5 ± 23.4
Clinician VAS 8.7 ± 11.5
SJC-28 0.71 ± 1.42
TJC-28 0.93 ± 1.96
DAS28-ESR 2.7 ± 1.1
DAS28-CRP 2.3 ± 0.9
CDAI 5.0 ± 5.2
SDAI 5.4 ± 5.7
HAQ 0.61 ± 0.71
Medication use, n (%)
DMARDs 306 (90.0%)
Biologic agents 186 (54.7%)
Prednisolone 89 (26.1%)
Methotrexate 232 (68.2%)
RA drugs ≥2 123 (36.2%)
ECG characteristics
HR, bpm 68.0 ± 10.9
RR interval, ms 896.7 ± 136.3
PR interval, ms 161.4 ± 25.2
QRS interval, ms 88.4 ± 12.1
QT interval, ms 396.0 ± 26.7
QTc interval, ms 420.0 ± 18.4
PAC, n (%) 42 (12.3%)
PVC, n (%) 24 (7.1%)
AF, n (%) 2 (0.6%)
Bradycardia, n (%) 80 (23.5%)
Conduction disorder, n (%) 31 (9.1%)
RBBB, n (%) 15 (4.4%)
LVH, n (%) 26 (7.6%)
QT prolongation, n (%) 14 (4.1%)